Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 10, 2022 (4 years ago)

Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDC #33342-052-10 & NDC # 33342-052-44, Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Affected NDCs 33342-0052-07 33342-0052-10 33342-0052-44

Compare with the code on your package — it is the most precise check available.

Drug: Hydrochlorothiazide Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Losartan potassium and Hydrochlorothiazide
NDC 33342-0052
LOSARTAN POTASSIUM 100 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 Tablet, Film Coated
Oral
Macleods Pharmaceuticals Limited Rx
Recalling firm
Macleods Pharma Usa Inc
NDC code
33342-052-07
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1164-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrochlorothiazide recalls

See all
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025

Other recalls by Macleods Pharma Usa Inc

All 2022 recalls
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023
Class II · Moderate risk

Eszopiclone Tablets

Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.

Terminated Failed specification Macleods Pharma Usa Inc NDC 33342-299-07 D-1174-2022